KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Accumulated Depreciation (2021 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Accumulated Depreciation for 5 consecutive years, with $15.4 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation rose 14.74% to $15.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.4 million through Dec 2025, up 14.74% year-over-year, with the annual reading at $15.4 million for FY2025, 14.74% up from the prior year.
  • Accumulated Depreciation for Q4 2025 was $15.4 million at Xenon Pharmaceuticals, up from $13.5 million in the prior quarter.
  • The five-year high for Accumulated Depreciation was $15.4 million in Q4 2025, with the low at $8.7 million in Q4 2022.
  • Average Accumulated Depreciation over 5 years is $12.4 million, with a median of $13.4 million recorded in 2021.
  • The sharpest move saw Accumulated Depreciation crashed 34.79% in 2022, then grew 29.25% in 2023.
  • Over 5 years, Accumulated Depreciation stood at $13.4 million in 2021, then plummeted by 34.79% to $8.7 million in 2022, then increased by 29.25% to $11.3 million in 2023, then increased by 19.67% to $13.5 million in 2024, then grew by 14.74% to $15.4 million in 2025.
  • According to Business Quant data, Accumulated Depreciation over the past three periods came in at $15.4 million, $13.5 million, and $11.3 million for Q4 2025, Q4 2024, and Q4 2023 respectively.